Aortic balloon valvuloplasty as a bridge-to-decision in patients with aortic stenosis
View Full Paper
Ask AI
Bookmark
Share
Key result
Following balloon aortic valvuloplasty for severe aortic stenosis, patients who underwent subsequent destination therapy (TAVI or AVR) had significantly lower 1-year mortality compared to those treated conservatively (13.3% vs 56.2%, HR 0.022).
Why the study?
BAV serves as a bridge for patients temporarily ineligible for AVR or TAVI, but evaluation of its efficacy, safety, outcomes, and factors affecting 12-month mortality was needed.
Population
47 consecutive patients with severe, symptomatic aortic stenosis undergoing BAV
Design
Single-center retrospective study
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
BAV may bridge high-risk AS patients to decisions; level 5 data leave optimal selection and long-term outcomes open.
Study Design
Type
Cohort (n=47)
Multicenter
No
Structured PICO
P
Population
47 elderly patients (mean age 76.8 years, 48.9% female) with severe, symptomatic aortic stenosis who were temporarily ineligible for surgical AVR or TAVI, followed for 1 year.
E
Exposure
Percutaneous balloon aortic valvuloplasty (BAV) using a single balloon (mean diameter 21 ±2.29 mm) as a bridge-to-decision (TAVI/AVR) or palliative care.
O
Outcome
Death and qualification for destination therapy (transcatheter aortic valve implantation or surgical aortic valve replacement) at 1 year.hard clinical
Main Result
Hazard Ratio: 0.022 (95% CI 0.001–0.29)
Absolute Event Rate: 13.3% vs 56.2%
p-value: p=0.003
Limitations
- Retrospective analysis based on treatment outcomes from a single center
- Small sample size compared to larger published registries
- Lack of a control group for the balloon aortic valvuloplasty procedure itself
- Differences in patient profiles (especially ejection fraction) compared to other studies
- Retrospective analysis from one center
- Small number of patients
- Profile of treated patients differs from other studies (especially in ejection fraction)
- No control group
Cite This Study
Wacławski et al. (2019) conducted a cohort in Severe, symptomatic aortic stenosis (n=47). Destination therapy (TAVI or AVR) after balloon aortic valvuloplasty vs. Conservative treatment after balloon aortic valvuloplasty was evaluated on 1-year mortality (HR 0.022, 95% CI 0.001-0.29, p=0.003). Following balloon aortic valvuloplasty for severe aortic stenosis, patients who underwent subsequent destination therapy (TAVI or AVR) had significantly lower 1-year mortality compared to those treated conservatively (13.3% vs 56.2%, HR 0.022).
View Full Paper
Ask AI
Bookmark
Share